Epilepsy
Epilepsy is a spectrum of non-communicable neurological disorders characterized by recurrent epileptic seizures, which are abnormal, excessive, and synchronized electrical discharges in the neurons. While there is no cure, seizures can often be managed with medications, surgical procedures, or a ketogenic diet, with varying degrees of social stigma experienced by those affected.
Health Outcomes
- Altered Endocannabinoid System Function Due to Specific Strain
- Altered Pyridoxine Concentration
- Confirmed Safety of Treatment
- Demonstrated Long-term Safety
- Enhanced Neurological Disorder Management
- Enhanced Neuropharmacological Function
- Improved Blood-Brain Barrier Function
- Improved Central Nervous System Function
- Improved Delta Power in EEG
- Improved Neurofibromatosis
- Improved Neurological Health
- Improved Neurological Symptoms
- Improved Neuroprotection
- Improved Parent/Caregiver Quality of Life
- Improved Seizure Control
- Improved Treatment Efficacy
- Improved Treatment Success
- Increased Acceptability of Use
- Increased Brain Creatine Level
- Increased Brain GABA Levels
- Increased Delta Power in EEG
- Increased GABA Content
- Increased GABAergic Signaling
- Increased Glycine Level
- Increased Need for Repeated Dosing
- Increased Neuronal Firing Threshold
- Increased Production of Beneficial Neurotransmitter GABA
- Increased Saliva Production
- Increased Systemic GABA Levels
- Modulated Endocannabinoid System
- Nervous System Dysfunction in Host
- No Change in Plasma GABA Levels
- Normalized EEG Pattern
- Preserved Hippocampal Neurogenesis
- Prevention of Neurological Disorders
- Reduced Brain Oxidative Stress
- Reduced Central Nervous System Symptom Severity
- Reduced Cortical Excitation
- Reduced Day School Absenteeism
- Reduced Episode Frequency
- Reduced Neurological Symptoms
- Reduced Neurotoxicity
- Reduced Relapse Rate
- Reduced Seizure Frequency
- Reduced cFos Expression in Brain Areas
- Regulation of Neuroactive Ligand Receptor Interaction Pathway
- Safe Drug Administration